Implant with structural members arranged around a ring

Information

  • Patent Grant
  • 11938039
  • Patent Number
    11,938,039
  • Date Filed
    Thursday, December 30, 2021
    2 years ago
  • Date Issued
    Tuesday, March 26, 2024
    a month ago
Abstract
An implant may include a body including a ring, the ring further defining an opening, and the body defining a transverse plane dividing the implant into a superior half and an inferior half. The ring may also define a radial direction and a circumferential direction. The implant may further include a first outer member attached to the ring, wherein the first outer member extends radially from the ring, wherein the first outer member defines one or more arches, and wherein the ring further defines a central channel extending through the implant.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of Bishop et al., U.S. Patent Application Publ. No. 2020/0229940, published Jul. 23, 2020, and entitled “Implant with Structural Members Arranged Around a Ring,” which is a continuation of Bishop et al., U.S. Patent Application Publ. No. 2018/0256351, published Sep. 13, 2018, and entitled “Implant with Structural Members Arranged Around a Ring.” The entire disclosures of the applications listed above are incorporated herein by reference.


BACKGROUND

The embodiments are generally directed to implants for supporting bone growth in a patient.


A variety of different implants are used in the body. Implants used in the body to stabilize an area and promote bone ingrowth provide both stability (i.e. minimal deformation under pressure over time) and space for bone ingrowth.


Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical treatment method used for the treatment of various morbidities such as degenerative disc disease, spondylolisthesis (slippage of a vertebra), spinal stenosis, scoliosis, fracture, infection or tumor. The aim of the spinal fusion procedure is to reduce instability and thus pain.


In preparation for the spinal fusion, most of the intervertebral disc is removed. An implant, the spinal fusion cage, may be placed between the vertebra to maintain spine alignment and disc height. The fusion, i.e. bone bridge, occurs between the endplates of the vertebrae.


SUMMARY

In one aspect, an implant includes a body including a ring with an opening. The body defines a transverse plane dividing the implant into a superior half and an inferior half. The ring defines a radial direction and a circumferential direction. The implant includes a bone contacting member attached to the ring, where the bone contacting member extends radially from the ring. The implant also includes a support member attached to the bone contacting member at an attachment region, where the support member extends in the circumferential direction.


In another aspect, an implant includes a body. The body defines a transverse plane dividing the implant into a superior half and an inferior half. The implant includes a first bone contacting member attached to the body and disposed within the superior half of the implant. The implant also includes a first support member attached to the first bone contacting member, the first support member being disposed within the superior half of the implant. The implant also includes a second bone contacting member attached to the body and disposed within the inferior half of the implant. The implant also includes a second support member attached to the second bone contacting member, the second support member being disposed within the inferior half of the implant. An end of the first support member is attached to an end of the second support member.


In another aspect, an implant includes a body and a plurality of bone contacting members extending from a central region of the body to a periphery of the body. Each of the bone contacting members in the plurality of bone contacting members extend radially away from the central region of the body.


Other systems, methods, features and advantages of the embodiments will be, or will become, apparent to one of ordinary skill in the art upon examination of the following figures and detailed description. It is intended that all such additional systems, methods, features and advantages be included within this description and this summary, be within the scope of the embodiments, and be protected by the following claims.





BRIEF DESCRIPTION OF THE DRAWINGS

The embodiments can be better understood with reference to the following drawings and description. The components in the figures are not necessarily to scale, with emphasis instead being placed upon illustrating the principles of the embodiments. Moreover, in the figures, like reference numerals designate corresponding parts throughout the different views.



FIG. 1 is a schematic isometric superior view of an embodiment of an implant;



FIG. 2 is a schematic isometric inferior view of the implant of FIG. 1;



FIG. 3 is a schematic isometric view of a body of the implant of FIG. 1 shown in isolation;



FIG. 4 is a schematic side view of the implant of FIG. 1;



FIG. 5 is a schematic isometric view of the implant of FIG. 1, including an enlarged cut-away view of a structural member;



FIG. 6 is a schematic isometric view of a plurality of support members arranged within the body of the implant of FIG. 1;



FIG. 7 is a schematic lateral side view of the implant of FIG. 1;



FIG. 8 is a schematic lateral side view of the implant of FIG. 1, in which the body has been removed for purposes of clarity;



FIG. 9 is a schematic isometric view of the implant of FIG. 1, in which member curves of several structural members are illustrated;



FIG. 10 is a schematic superior view of an embodiment of an implant;



FIG. 11 is a schematic depicting an implant attached to an implant tool, and where the implant is covered with a bone growth promoting material, according to an embodiment;



FIG. 12 is a schematic isometric view of an implant being positioned for insertion between two vertebrae, according to an embodiment;



FIG. 13 is a schematic isometric view of the implant of FIG. 12 inserted between the two vertebrae;



FIG. 14 is a schematic side view of the implant of FIG. 13 including a partial cut-away view of a central cavity;



FIG. 15 is a schematic side view of the implant of FIG. 13 indicating areas of new bone growth;



FIG. 16 is a schematic side view of the implant of FIG. 13 indicating areas of new bone growth;



FIG. 17 is a schematic isometric view of the implant of FIG. 13 including an enlarged view of the superior side of the implant;



FIG. 18 is a schematic isometric view of the implant of FIG. 13 indicating areas of new bone growth on the superior side of the implant;



FIG. 19 is a schematic isometric view of the implant of FIG. 13 indicating areas of new bone growth on the superior side of the implant; and



FIG. 20 is a schematic isometric view of new bone growth covering the implant of FIG. 13.





DETAILED DESCRIPTION

The embodiments described herein are directed to an implant for use in a spine. The embodiments include implants with a body and one or more structural members. In addition to the various provisions discussed below, any embodiments may make use of any of the body/support structures, frames, plates, coils or other structures disclosed in Morris et al., U.S. Pat. No. 9,918,849, issued on Mar. 20, 2018, and titled “Coiled Implants and Systems and Methods of Use Thereof,” which is hereby incorporated by reference in its entirety. For purposes of convenience, the Morris application will be referred to throughout the application as “The Coiled Implant Application”. Also, any embodiments may make use of any of the body/support structures, elements, frames, plates or other structures disclosed in McShane III et al., U.S. Publication Number 2019/0000642, published on Jan. 3, 2019, and titled “Implant with Arched Bone Contacting Elements,” which is hereby incorporated by reference in its entirety. Also, any embodiments may make use of any of the body/support structures, elements, frames, plates or other structures disclosed in McShane III et al., U.S. Publication Number 2018/0110626, published on Apr. 26, 2018, and titled “Implant with Protected Fusion Zones,” which is hereby incorporated by reference in its entirety and referred to as “The Protective Fusion Zones application”.



FIGS. 1 and 2 illustrate isometric views of an embodiment of an implant 100, which may be alternatively referred to as a device. Specifically, FIG. 1 is an isometric view of a top or superior side of implant 100, while FIG. 2 is an isometric view of a bottom or inferior side of implant 100. Implant 100 may also be referred to as a cage or fusion device. In some embodiments, implant 100 is configured to be implanted within a portion of the human body. In some embodiments, implant 100 may be configured for implantation into the spine. In some embodiments, implant 100 may be a spinal fusion implant, or spinal fusion device, that is inserted between adjacent vertebrae to provide support and/or facilitate fusion between the vertebrae.


In some embodiments, implant 100 may include a body 102. Body 102 may generally provide a frame or skeleton for implant 100. In some embodiments, implant 100 may also include a plurality of structural members 104. Plurality of structural members 104 may be fixedly attached to, and/or continuously formed (or “integrally formed”) with, body 102. As used herein, the term “fixedly attached” shall refer to two components joined in a manner such that the components may not be readily separated (for example, without destroying one or both components).


As used herein, each structural member comprises a distinctive member or element that spans a portion of an implant. Structural members may overlap or intersect, similar to elements in a lattice or other 3D mesh structure. Some embodiments may use structural members in which the length of the member is greater than its width and its thickness. In embodiments where a structural member has an approximately circular cross-sectional shape, the structural member has a length greater than its diameter. In the embodiments seen in FIGS. 1-2, each structural member is seen to have an approximately rounded or circular cross-sectional shape (i.e., the member has the geometry of a solid tube). However, in other embodiments, a structural member could have any other cross-sectional shape, including, but not limited to, various polygonal cross-sectional shapes, as well as any other regular and/or irregular cross-sectional shapes. In some cases, for example, the cross-sectional size and/or shape of a structural member could vary along its length (e.g., the diameter could change along its length).


For purposes of clarity, reference is made to various directional adjectives throughout the detailed description and in the claims. As used herein, the term “anterior” refers to a side or portion of an implant that is intended to be oriented towards the front of the human body when the implant has been placed in the body. Likewise, the term “posterior” refers to a side or portion of an implant that is intended to be oriented towards the back of the human body following implantation. In addition, the term “superior” refers to a side or portion of an implant that is intended to be oriented towards a top (e.g., the head) of the body while “inferior” refers to a side or portion of an implant that is intended to be oriented towards a bottom of the body. Reference is also made herein to “lateral” sides or portions of an implant, which are sides, or portions, facing along a lateral direction of the body (which correspond with the left or right sides of a patient).


In FIGS. 1-2, implant 100 is understood to be configured with an anterior side 110 and a posterior side 112. Implant 100 may also include a first lateral side 114 and a second lateral side 116 that extend between the posterior side 112 and the anterior side 110 on opposing sides of implant 100. Furthermore, implant 100 may also include a superior side 130 and an inferior side 140.


Reference is also made to directions or axes that are relative to the implant itself, rather than to its intended orientation with regards to the body. For example, the term “distal” refers to a part that is located further from a center of an implant, while the term “proximal” refers to a part that is located closer to the center of the implant. As used herein, the “center of the implant” could be the center of mass and/or a central plane and/or another centrally located reference surface.


An implant may also be associated with various axes. Referring to FIG. 1, implant 100 may be associated with a longitudinal axis 120 that extends along the longest dimension of implant 100 between first lateral side 114 and second lateral side 116. Additionally, implant 100 may be associated with a posterior-anterior axis 122 (also referred to as a “widthwise axis”) that extends along the widthwise dimension of implant 100, between posterior side 112 and anterior side 110. Moreover, implant 100 may be associated with a vertical axis 124 that extends along the thickness dimension of implant 100 and which is generally perpendicular to both longitudinal axis 120 and posterior-anterior axis 122.


An implant may also be associated with various reference planes or surfaces. As used herein, the term “median plane” refers to a vertical plane which passes from the anterior side to the posterior side of the implant, dividing the implant into right and left halves, or lateral halves. As used herein, the term “transverse plane” refers to a horizontal plane located in the center of the implant that divides the implant into superior and inferior halves. As used herein, the term “coronal plane” refers to a vertical plane located in the center of the implant that divides the implant into anterior and posterior halves. In some embodiments, the implant is symmetric about two planes, such as the median and the transverse plane.



FIG. 3 illustrates a schematic isometric view of body 102 in isolation, with plurality of structural members 104 removed for purposes of clarity. In some embodiments, a body could include distinct frame portions that are oriented in different directions. In the embodiment shown in FIG. 3, body 102 includes a peripheral frame portion 200, also referred to as simply “peripheral portion 200”. In some embodiments, peripheral portion 200 has a longest dimension aligned with longitudinal axis 120 and a widthwise dimension (e.g., the second longest dimension) aligned with posterior-anterior axis 122 of implant 100 (see FIGS. 1 and 2). Peripheral frame portion 200 comprises a first lateral frame portion 202, a second lateral frame portion 204 and a posterior frame portion 206, which primarily lie in the transverse plane.


In some embodiments, one or more sides of an implant (including lateral sides and/or anterior/posterior sides) could include a vertically oriented peripheral frame portion. In the embodiment of FIG. 3, body 102 is seen to include a vertically oriented peripheral frame portion 208 disposed at anterior side 110, which may also be referred to as an “anterior wall” of implant 100. In contrast, posterior side 112 lacks any frame portion or wall that extends vertically beyond the thickness of peripheral portion 200 in the embodiments of FIGS. 3-4. The presence of vertically oriented peripheral frame portion 208 may improve support and strength against vertical loads applied along the anterior side of the spine.


Although the present embodiment uses a vertically oriented frame or wall on the anterior side of implant 100, in other embodiments, a vertically oriented frame or wall could be located on the posterior side of implant 100 and/or on a lateral side of implant 100. In still other embodiments, the implant may lack any vertical walls along its perimeter (i.e., along the posterior, anterior or lateral sides).


Embodiments may include one or more rings. In some embodiments, an implant could include two or more rings that are connected in a ring assembly. As seen in FIG. 3, body 102 includes a ring assembly 220. Ring assembly 220 is further comprised of a superior ring 222 and an inferior ring 224. Additionally, ring assembly 220 includes a first support 226 and a second support 228 which extend through an interior region (and intersect the transverse plane) of implant 100 and join superior ring 222 and inferior ring 224.


As seen in FIG. 3, ring assembly 220 may be arranged to form a hollow cylinder, which includes openings 230. This geometry may provide a tubular space (central cavity 231) through which bone growth from opposing vertebrae can extend through and fuse at the center of the implant, thereby forming a strong cylindrical column of bone growth. Furthermore, the presence of openings 230 may allow new bone growth to extend from the column and fuse with bone growth occurring in adjacent regions of the interior of implant 100. Optionally, in other embodiments, a ring assembly may comprise continuous cylindrical walls with no openings.


In different embodiments, the location of a ring assembly could vary. For purposes of characterizing possible locations of a ring assembly, an implant may be divided into a first lateral side region, a second lateral side region and a central region disposed between the first lateral side region and the second lateral side region. In the exemplary embodiment of FIG. 3, implant 100 includes a first lateral side region 240, a central region 242 and a second lateral side region 244. In the exemplary embodiment, therefore, ring assembly 220 is disposed in central region 242 and approximately equally spaced away from opposing lateral ends. Of course, in other embodiments, ring assembly 220 could be disposed in first lateral side region 240 or second lateral side region 244.


It may be appreciated that in other embodiments a ring assembly could be disposed centrally with respect to a posterior/anterior direction. Though, in the present embodiment, ring assembly 220 extends the full distance between the posterior and anterior edges of implant 100.


In different embodiments, the shape of a ring could vary. In the exemplary embodiment, superior ring 222 and inferior ring 224 each have an oval-like shape. However, in other embodiments, a ring could have any other shape including, but not limited to, a rounded shape, a circular shape, a triangular shape, a square shape, a polygonal shape, a regular shape, an irregular shape, etc.


A ring assembly, including a superior ring and an inferior ring, could be attached to other portions of the implant in various ways. In some embodiments, a ring assembly may be attached directly to a peripheral frame portion of a body. In other embodiments, a ring assembly could be attached to the body by way of one or more structural members. In the exemplary embodiment, ring assembly 220 is attached directly to both peripheral frame portion 206 and vertically oriented peripheral frame portion 208, while also being attached to a plurality of structural members (see FIGS. 1-2).



FIG. 4 is a side view of an embodiment of implant 100. In some embodiments, vertically oriented peripheral frame portion 208 could include openings. In other embodiments, vertically oriented peripheral frame portion 208 may not include openings. In some embodiments, openings in a frame portion could provide an access point for inserting bone graft material or BGPM into an interior of an implant. The number, size and/or shape of openings in vertically oriented peripheral frame portion 208 could vary. In some cases, three or more openings could be used. In other cases, two openings could be used. In still other cases, a single opening could be used. Exemplary shapes for openings that could be used include, but are not limited to, rounded openings, rectangular openings, polygonal openings, regular openings and/or irregular openings. In the embodiment of FIGS. 3-4, vertically oriented peripheral frame portion 208 includes two large oval-shaped windows that may facilitate insertion of bone graft material (or BGMP) into an interior of the implant. Specifically, vertically oriented peripheral frame portion 208 includes first window 210 and second window 212.


Some embodiments can include provisions that facilitate implantation, including insertion and/or fixation of the implant. Some embodiments can include a fastener receiving portion. For example, as best seen in FIGS. 1-2, implant 100 includes a fastener receiving portion 160. Fastener receiving portion 160 includes a threaded opening 162 and a reinforced collar 164 to support threaded opening 162. In some embodiments, threaded opening 162 may be configured to receive a tool with a corresponding threaded tip to facilitate implantation of implant 100. In some embodiments, threaded opening 162 may be used with a screw to help attach implant 100 to a bone or another fixation device. In other embodiments, any other features for receiving fasteners and/or implantation tools could be incorporated into implant 100.


In some embodiments, an implant can be configured with one or more symmetries. In some cases, an implant may have a mirrored symmetry about one or more reference planes.


Referring to FIGS. 1 and 2, implant 100 may include at least one mirror symmetry. For purposes of reference, implant 100 may be split into a superior half and an inferior half. Here, the “superior half” of implant 100 includes the portions of body 102 and plurality of structural members 104 disposed above the transverse plane. Likewise, the “inferior half” of implant 100 includes the portions of body 102 and plurality of structural members 104 disposed below the transverse.


With respect to the transverse plane (which coincides generally with the plane defined by first lateral frame portion 202, second lateral frame portion 204 and posterior frame portion 206), it may be seen that the superior half of implant 100 mirrors the inferior half of implant 100, at least approximately. This includes not only the geometry of the body but also the shape, size and orientations of each structural member.


Moreover, with respect to the median plane (which approximately divides implant 100 into two lateral halves), it may be seen that two lateral halves mirror one another approximately. This includes not only the geometry of the body but also the shape, size and orientations of each structural member.


An implant may include two or more kinds of structural members (or structural elements). In some embodiments, an implant can include one or more bone contacting structural members, or simply “bone contacting members”. Bone contacting members may generally be fully exposed on the outer surfaces of an implant, including along the superior and inferior sides of the implant. Thus, bone contacting members may be alternatively referred to as “outer members”.


In some embodiments, an implant can include one or more structural members that provide support to one or more bone contacting members. Such supporting structural members may be referred to as “support members”. In some embodiments, at least some portions of each support member may be hidden or covered by a bone contacting member or another element of the implant. Thus, support members may also be characterized as “inner members” as they are generally disposed inwardly of the bone contacting members.



FIG. 5 illustrates a schematic isometric view of implant 100, according to an embodiment. As seen in FIG. 5, implant 100 may include a plurality of bone contacting members 180 as well as a plurality of support members 182. As best shown in FIGS. 1-2, plurality of structural members 104 are arranged in four distinct quadrants on implant 100: a first quadrant associated with superior side 130 and first lateral side region 240; a second quadrant associated with superior side 130 and a second lateral side region 244; a third quadrant associated with inferior side 140 and first lateral side region 240; and a fourth quadrant associated with inferior side 140 and second lateral side region 244.


The following discussion discusses exemplary structural members in some, but not all, of the quadrants of implant 100. However, it may be appreciated that similar properties and principles of the specific structural members discussed here may apply to structural members in any of the remaining quadrants.


In some embodiments, one or more structural members could be closed loops without ends. In other embodiments, at least some structural member comprises two ends. In some cases, structural members with two ends could include one or more ends that are attached to another structural member. In other cases, structural members with two ends could be arranged so that both ends are attached to a portion of a body of an implant. In the exemplary embodiment depicted in FIG. 5, each structural member includes two ends, with each end being attached to some portion of body 102, or attached to another structural member, of implant 100.


In some embodiments, an implant may include at least one bone contacting member with one end attached to a frame portion and another end attached to a central ring. For example, as seen in FIG. 5, a bone contacting member 300 includes a first end 302 attached to superior ring 222 and a second end 304 attached to first lateral frame 202.


In different embodiments, support members could be attached to different portions of an implant. In some embodiments, one or more ends of a support member could be attached to a peripheral frame portion of a body. In other embodiments, one or more ends could be attached to another support member. In still other embodiments, one or more portions of a support member could be attached to a bone contacting member. In one embodiment, each support member may be attached to a peripheral frame portion of the body, at least one bone contacting member, and at least one other support member.


In the exemplary embodiment of FIG. 5, each support member includes one end that is attached to a peripheral frame portion. For example, support member 340 includes a first end 342 that is attached to posterior frame portion 206. Likewise, the remaining support members of plurality of support members 182 each have an end attached to either peripheral frame portion 206 or vertically oriented peripheral frame portion 208.


Embodiments may include provisions to minimize the number of bars or other supports needed. Some embodiments may include provisions that eliminate the need for any internal supports extending between peripheral frame portion 200 (shown in FIG. 5) and ring assembly 220, thereby increasing the interior volume available to receive new bone growth. In some embodiments, support members from opposing superior and inferior sides of an implant may attach directly to one another, thereby eliminating the need for additional longitudinally running structures to receive the support members.



FIG. 6 is a schematic isometric view of plurality of support members 182 with body 102 shown in phantom for purposes of clarity. FIG. 7 illustrates a schematic lateral end view of implant 100, while FIG. 8 illustrates a similar view with body 102 removed for purposes of illustration. As seen in FIGS. 6-8, each support member includes an end that is joined to three other support members at an area adjacent the transverse plane. As an example, first superior support member 402, second superior support member 404, first inferior support member 406 and second inferior support member 408 are all joined at an attachment region 410 that is located approximately in the transverse plane of implant 100. Specifically, as best seen in FIG. 8, an end 403 of first superior support member 402, an end 405 of second superior support member 404, an end 407 of first inferior support member 406 and an end 409 of second inferior support member 408 are all joined together. Using this arrangement, the support members provide reinforcement and support in both the posterior-anterior directions and vertical directions of implant 100 without requiring additional support elements (e.g., longitudinally running beams, bars or plates) that would serve as attachment points for the support members in the center of the implant.


In some embodiments, bone contacting members may be disposed distal to support members, with bone contacting members generally disposed further outwards along the superior and inferior sides of an implant. Thus, bone contacting members may generally be disposed closer to the vertebral end plates following implantation into the spine. Moreover, at regions where a bone contacting member is attached to a support member, the attached portion of the bone contacting member may be disposed distal to the attached portion of the inner member. As one example, FIG. 5 illustrates a schematic isometric view of implant 100 including an enlarged cross-sectional view of an attachment region 189 between bone contacting member 370 and support member 390. Here, bone contacting member 370 is seen to extend up and over support member 390. Moreover, bone contacting member 370 is seen to be located distally to support member 390. Here, distally is intended to mean disposed further from the transverse plane of implant 100.


Embodiments can include provisions for protecting bone growth along and adjacent to bone contacting members of an implant. In some embodiments, a bone contacting member can be configured with a geometry that helps to protect new bone growth in selected regions or “protected fusion zones”. In some embodiments, a bone contacting member can have a spiral, helical or twisted geometry that provide a series of such protected fusion zones for enhanced bone growth.


Some bone contacting members may have a generalized helical geometry. As used herein, a “generalized helical geometry” or “spiraling geometry” refers to a geometry where a part (portion, member, etc.) winds, turns, twists, rotates or is otherwise curved around a fixed path. In some cases, the fixed path could be straight. In other cases, the fixed path can be curved. In the present embodiments, for example, the fixed path is generally a combination of straight segments and curved segments.


Curves having a generalized helical geometry (also referred to as generalized helical curves) may be characterized by “coils”, “turns” or “windings” about a fixed path. Exemplary parameters that may characterize the specific geometry of a generalized helical curve can include coil diameter (including both a major and minor diameter) and the pitch (i.e., spacing between adjacent coils). In some cases, the “amplitude” of a coil or loop may also be used to describe the diameter or widthwise dimension of the coil or loop. Each of these parameters could be constant or could vary over the length of a generalized helical curve.


Generalized helical curves need not be circular or even round. In some embodiments, for example, a generalized helical curve could have linearly segmented shape (or locally polygonal shape) such that each “coil” or “turn” is comprised of straight line segments rather than arcs or other curved segments. Generalized helical curves may also include combinations of curved and straight segments. Examples of generalized helical curves are shown and described in The Protected Fusion Zones Application.


For purposes of characterizing the geometry of one or more structural members, each structural member can be understood to have a “central member curve”. The central member curve of each structural member may be defined as a curve that extends along the length of the structural member such that each point along the curve is centrally positioned within the structural member.


In embodiments where a structural member winds or loops around a fixed path with an amplitude or diameter that is much greater than the cross-sectional diameter of the structural member itself, the structural member may be wound into visible distinct coils. Such coils are discussed in thorough detail in the Coiled Implant Application. In other embodiments, however, a structural member could be wound around a fixed path with an amplitude or diameter that is less than the cross-sectional diameter of the structural member itself. In such a case the resulting geometry of a structural member may appear to be twisted, but the geometry may lack the distinct coils seen in the Coiled Implant Application. However, it may be appreciated that while the outermost surface of such a structural member may not exhibit distinct coils, the central member curve of the structural member does have such coils or turns and moreover has a clear generalized helical geometry.



FIG. 9 is a schematic isometric view of implant 100 where the structural members have been removed for purposes of clarity. To depict the geometry of the structural members, the central member curve of several structural members is shown. Specifically, central member curve 520 is shown, which corresponds to the geometry of bone contacting member 300. Additionally, central member curve 504 and central member curve 506 are shown, which correspond with the geometry of support members providing support to bone contacting member 300.


As previously discussed, bone contacting member 300 (FIG. 5) exhibits a twisted geometry indicative of a spiral or helix. However, since the winding occurs with an amplitude much smaller than the thickness of bone contacting member 300, the geometry of the part may be difficult to discern. The generalized helical geometry of bone contacting member 300 becomes much clearer when the geometry of its central member curve 520 (which is clearly seen in FIG. 9) is considered as it winds around a fixed path 540 (also shown in FIG. 9).


In different embodiments, the winding diameter of a helical structural member could vary. In the exemplary embodiment, a winding diameter 552 of the coils or turns in central member curve 520 are smaller than the diameter of bone contacting member 300. In other embodiments, the cross-sectional diameter of a bone contacting member could be less than a corresponding winding diameter of the coils or turns of its central member curve. In such an embodiment, the bone contacting member would be configured in a series of distinct coils.


A bone contacting member may not have a generalized helical geometry through its entire length. Instead, its central member curve may be configured with a winding segment where the central member curve completes several full turns (three in FIG. 9) around a fixed path. Away from the winding segment, its central member curve may not include any turns, twists, etc.


Although the present embodiment includes at least one bone contacting member with a winding segment that makes one or more full turns around a fixed path, other embodiments could be configured with central member curves that only make partial turns around a fixed path.


While the description here has focused on the geometry of a single bone contacting member 300, it may be appreciated that some or all of the remaining bone contacting members in plurality of structural members 104 may have a similar generalized helical geometry. It may be further appreciated that two different bone contacting members could have slightly different geometries, with distinct bone contacting member curves that include variations in the number of windings, shape of the windings, etc.


In some embodiments, an implant can include bone contacting members that are locally helical over small distances compared to the length, width or height of the implant. For example, implant 100 may be characterized as having bone contacting members that are locally helical or locally spiraling, rather than globally helical. In particular, each bone contacting member of implant 100 is bounded within a single quadrant of implant 100 and does not cross the transverse plane or the median plane of implant 100. Thus, a full turn of the bone contacting members is accomplished over distances that are much smaller than half the length, width or height of the implant. This allows multiple windings within each quadrant of the implant and also results in the pitch between windings being smaller than the length, width or height of the implant. For example, in FIG. 9, central member curve 520 has a pitch 529 between adjacent windings or turns that is less than one third of the length of bone contacting member 300. Pitch 529 is also less than one tenth of the length of implant 100. This relatively small pitch size allows for a greater number of proximal surface regions along each bone contacting member, thereby increasing the number of available protected fusion zones of the inferior and superior surfaces of implant 100.


In some embodiments, the helix-like geometry of bone contacting members provides distinct regions exposed on the superior and inferior sides of an implant. For example, referring to FIG. 5, each bone contacting member includes one or more distal regions 360 that may be seen as “peaks” in the bone contacting member along the superior side 130 of implant 100. In at least some embodiments, these distal regions 360 may be flattened or “smoothed” to provide a flat or smooth distal-most surface on superior side 130 (and inferior side 140), thereby facilitating contact with adjacent vertebrae. In other embodiments, a distal surface region may be curved. In some cases, the distal surface region could have a curvature that matches the curvature of the adjacent surface regions of the bone contacting member. In other cases, the distal surface region could have a different curvature (e.g., more convex) than adjacent surface regions of the bone contacting member.


Bone contacting members may also include proximal regions 362 that are configured as “valleys” in the bone contacting member along the superior side 130 of implant 100. Whereas the distal regions 360 may come into contact with the vertebrae during and following implantation of implant 100, proximal regions 362 may be recessed or spaced apart from direct contact with the vertebrae, at least before new bone growth has developed.


As a particular example, FIG. 5 includes an enlarged cross-sectional view of a portion of a bone contacting member 370 and underlying support member 390. Specifically, an outwardly facing surface portion 372 of bone contacting member 370 is visible. As used herein, the “outwardly facing surface portion” of a bone contacting member is the portion of the surface of the bone contacting member facing towards a vertebra during implantation, or facing away from an interior of the implant. Outwardly facing surface portion 372 includes a first distal surface region 380, a proximal surface region 382 and a second distal surface region 384. As discussed in further detail below, this local geometry provides a series of protected fusion zones adjacent each proximal surface region, where new bone growth can be protected during early bone fusion.


While bone contacting members may have generalized helical geometries, the geometries of the support members may be selected to enhance strength and support. In some embodiments, support members could have a generally tube-like (solid) shape and may extend in simple curves from one portion of a body to another. In some cases, the central member curve of a support member may be smoothly curved without any local twists, windings or coils.


Thus, it may be appreciated, that in some embodiments, support members may generally be shorter and their geometry may be more arch-like to improve strength and provide increased support for the bone contacting members. In contrast, the bone contacting members may generally have a longer length and may be less arch-like in shape relative to the support members, as the bone contacting members need to extend across as much of the superior/inferior sides of an implant as possible to provide contact with the vertebrae.


While some embodiments include bone contacting members with generalized helical geometries and support members with arch-like geometries, in other embodiments any structural member could be configured with any type of geometry. For example, in another embodiment, one or more support members could have a generalized helical geometry that create protected fusion zones along the support members. In still another embodiment, one or more bone contacting members could have an arch-like geometry.


In different embodiments, the attachment between a support member and a bone contacting member could occur at various locations. In some embodiments, a support member could be attached near a distal surface region along the outer surface of a bone contacting member. In other embodiments, a support member could be attached near a proximal surface region along the outer surface of a bone contacting member.


In some embodiments, each support member is configured to attach to a corresponding bone contacting member at a location adjacent (or underlying) a proximal surface region of the bone contacting member. For example, as shown in FIG. 5, an attachment region 189 of support member 390 is attached to bone contacting member 300 at a location corresponding to proximal surface region 382 of bone contacting member 300. Likewise, every other support member of implant 100 attaches to one or more bone contacting members only at locations corresponding to proximal surface regions.


This configuration provides for protected fusion zones that encompass the space immediately adjacent the proximal regions. The protected fusion zones are locations along the superior/inferior surfaces of an implant where new bone growth can be partially protected from forces applied to the bone contacting members by adjacent support members or directly from a vertebra.


By configuring one or more bone contacting members with at least one helical portion, the bone contacting member may provide one or more protected fusion zones on the superior and inferior sides of an implant. These protected fusion zones encompass the space immediately adjacent the proximal regions of the bone contacting members. The recessed spaces provided by the proximal regions allow for pockets of new bone growth adjacent initial fusion that may occur at the distal regions. Moreover, because the support members are attached near the proximal surface regions, and not at the distal surface regions, forces applied to the bone contacting members by either the support members or by a vertebra can be directed away from the protected fusion zones, thereby minimizing the disturbance of new bone growth.



FIG. 10 is a schematic top down view of an implant 600, according to an embodiment. Referring to FIG. 10, implant 600 includes body 601 comprising peripheral frame portion 602, peripheral frame portion 604, peripheral frame portion 606 and peripheral frame portion 608. Additionally, body 601 comprises ring 609 defining a central opening 650.


For purposes of reference, central opening 650 (and ring 609) define a radial direction 599 and a circumferential direction 598. Here, radial direction 599 extends outwardly from a center of central opening 650, while circumferential direction 598 is an angular direction that is perpendicular with radial direction 599.


In different embodiments, the orientation of bone contacting members and/or support members could vary. In some embodiments, bone contacting members may be oriented radially away from a center of an implant. In some embodiments, support members may be oriented in a circumferential (or angular) direction that rotates about a center of an implant. In other embodiments, however, bone contacting members could be oriented in a circumferential direction while support members could be oriented in a radial direction. In still other embodiments, one or more structural elements could be oriented in directions orthogonal to the length and/or width of an implant, rather than in radial and/or circumferential directions.


Implant 600 also includes plurality of bone contacting members 630 and plurality of support members 632. As seen in FIG. 10, plurality of bone contacting members 630, which includes first bone contacting member 611, second bone contacting member 612, third bone contacting member 613 and fourth bone contacting member 614 may each extend in radial direction 599 (i.e., outwardly from central opening 650 and ring 609). For example, first bone contacting member 611 extends radially from ring 609 to peripheral frame portion 602. Second bone contacting member 612 also extends radially from ring 609 to peripheral frame portion 602, though second bone contacting element 612 has a different angular (or circumferential) position along circumferential direction 598. Also, third bone contacting member 613 extends radially from ring 609 to peripheral frame portion 604. Fourth bone contacting member 614 also extends radially from ring 609 to peripheral frame portion 604, though fourth bone contacting element 614 has a different angular (or circumferential) position along circumferential direction 598.


As seen in FIG. 10, plurality of support members 632 is further comprised of first support member 621, second support member 622, third support member 623, fourth support member 624, fifth support member 625, sixth support member 626, seventh support member 627 and eighth support member 628. Each of these support members may be oriented approximately in the circumferential direction 598. For example, first support member 621 extends from peripheral frame portion 606 to its attachment with second support member 622 along a path 640 that is approximately parallel with the circumferential direction 598. Likewise, second support member 622 extends from its attachment to first support member 621 to peripheral frame portion 608 along a path 642 that is also approximately parallel with circumferential direction 598. Moreover, it is clear from FIG. 10 that first support member 621 is approximately perpendicular with (radially oriented) first bone contacting member 611 and that second support member 622 is approximately perpendicular with (radially oriented) second bone contacting member 612. Similarly, each remaining support member in plurality of support members 632 is oriented approximately parallel with circumferential direction 598 and is also approximately perpendicular to a bone contacting member to which it attaches.


The embodiment of FIG. 10 may be characterized as having structural members arranged in a web-like or spider web-like pattern. Moreover, it may be appreciated that while only one side of implant 600 is shown, an opposing side may likewise include a central ring and structural members oriented in a similar web-like pattern.


This web-like pattern provides radially oriented structural members (bone contacting members) that may help improve strength in multiple directions simultaneously (i.e., the longitudinal and lateral directions). This may also help direct new bone growth from the center of the device (which includes a large central cavity for bone growth) towards the corners and periphery of the device. Moreover, the circumferential orientation of some structural members (support members) in this web-like pattern also improves the strength of the device in multiple directions simultaneously and in directions orthogonal to the radially oriented structural members.


The arrangement of structural members with the body may also be designed to achieve a desired total open volume. As used herein a total volume is the combined volume of any openings between structural members, any openings in the body, or between structural members and the body. This open configuration may facilitate bone growth in and through the implant. A portion, or substantially all of, the open spaces is optionally filled with a bone graft or bone growth promoting material prior to or after insertion of the implant to facilitate bone growth.


The total volume of the open spaces (also referred to simply as the open space volume) within any particular implant is dependent on the overall dimension of the implant as well as the size and dimension of individual components within the implant including structural members, frame portions, etc. The open space volume may range from about 20% to 80% of the volume of the implant. In some embodiments, implant 100 may have an open space volume that is between 25% and 80% of the implant's total volume. In still further embodiments, implant 100 may have an open space volume that is between 40% and 75% of the total implant volume.



FIGS. 11-13 illustrate various schematic views of a process of implanting an implant 600. Referring first to FIGS. 11-13, the implantation process may begin with the application of a bone growth promoting material, also referred to as a BGPM, to the implant. As used herein, a “bone growth promoting material” is any material that helps bone growth. Bone growth promoting materials may include provisions that are freeze dried onto a surface or adhered to the metal through the use of linker molecules or a binder. Examples of bone growth promoting materials are any materials including bone morphogenetic proteins (BMPs), such as BMP-1, BMP-2, BMP-4, BMP-6, and BMP-7. These are hormones that convert stem cells into bone forming cells. Further examples include recombinant human BMPs (rhBMPs), such as rhBMP-2, rhBMP-4, and rhBMP-7. Still further examples include platelet derived growth factor (PDGF), fibroblast growth factor (FGF), collagen, BMP mimetic peptides, as well as RGD peptides. Generally, combinations of these chemicals may also be used. These chemicals can be applied using a sponge, matrix or gel.


Some bone growth promoting materials may also be applied to an implantable prosthesis through the use of a plasma spray or electrochemical techniques. Examples of these materials include, but are not limited to, hydroxyapatite, beta tri-calcium phosphate, calcium sulfate, calcium carbonate, as well as other chemicals.


A bone growth promoting material can include, or may be used in combination with, a bone graft or a bone graft substitute. A variety of materials may serve as bone grafts or bone graft substitutes, including autografts (harvested from the iliac crest of the patient's body), allografts, demineralized bone matrix, and various synthetic materials.


Some embodiments may use autograft. Autograft provides the spinal fusion with calcium collagen scaffolding for the new bone to grow on (osteoconduction). Additionally, autograft contains bone-growing cells, mesenchymal stem cells and osteoblast that regenerate bone. Lastly, autograft contains bone-growing proteins, including bone morphogenic proteins (BMPs), to foster new bone growth in the patient.


Bone graft substitutes may comprise synthetic materials including calcium phosphates or hydroxyapatites, stem cell containing products which combine stem cells with one of the other classes of bone graft substitutes, and growth factor containing matrices such as INFUSE® (rhBMP-2-containing bone graft) from Medtronic, Inc.


It should be understood that the provisions listed here are not meant to be an exhaustive list of possible bone growth promoting materials, bone grafts or bone graft substitutes.


In some embodiments, BGPM may be applied to one or more outer surfaces of an implant. In other embodiments, BGPM may be applied to internal volumes within an implant. In still other embodiments, BGPM may be applied to both external surfaces and internally within an implant. As seen in FIGS. 11-13, a BGPM 700 has been placed inside an interior of implant 600 and also applied on superior and inferior surfaces of implant 600. Moreover, as shown in FIG. 11, BGPM 700 has been inserted through (and extends through) a first window 662 and a second window 664 of implant 600.



FIGS. 12 and 13 show schematic views of the implant pre-implantation (FIG. 12) and post-implantation (FIG. 13). Once implanted, implant 600 may be disposed between, and in direct contact with, adjacent vertebra. Specifically, a superior side 702 of implant 600 is disposed against first vertebra 712. Likewise, an inferior side 704 of implant 600 is disposed against second vertebra 714.


In different embodiments, implantation methods could vary. In some embodiments, implant 600 may be secured to an implantation tool 701 (partially seen in FIGS. 11-12) that is used to drive implant 600 into the spine. Implantation tool 701 could be any rod, ram, pole or other device that can be hammered, rammed, or otherwise driven to position implant 600 between adjacent vertebrae. As previously mentioned, in some cases, an implantation tool could be attached to implant 600 at a fastener receiving portion (i.e., a threaded opening for receiving a threaded shaft from a tool).



FIGS. 14-20 depict a schematic sequence of bone growth throughout implant 600, including through central cavity 671 (FIGS. 14-16), as well as along the superior and inferior sides of implant 600 (FIGS. 17-20).



FIGS. 14-16 depict a partial cross-sectional view of implant 600 just after implantation between vertebra 712 and vertebra 714. Here, BGPM 700 fills an interior of implant 600 and also coats the superior and inferior surfaces in contact with the vertebrae.


Initial bone fusion and growth may occur where the vertebrae are in contact with BGPM 700. With time, new bone growth begins to extend along the inferior and superior surfaces of implant 600 as well as into central cavity 671, as seen in FIG. 15. For example, in FIG. 15, new bone growth region 720 extends from vertebra 712 into central cavity 671 while new bone growth region 722 extends from vertebra 714 into central cavity 671. New bone growth regions 726 may also extend into the interior spaces of implant 600 that are adjacent to central cavity 671.


Eventually, as seen in FIG. 16, a solid column of new bone growth 724 may form throughout central cavity 671. This new bone growth in central cavity 671, along with new bone growth associated with other regions of the interior and exterior of implant 600, helps to fuse vertebra 712 and vertebra 714.



FIGS. 17-20 depict a schematic sequence of bone growth along a superior surface 675 of implant 600. This new bone growth may occur prior to, simultaneously with, or after bone has grown through the interior of implant 600 as described above. While only the superior side is shown in FIGS. 17-20, it may be appreciated that similar bone growth patterns may occur on the inferior side of the implant simultaneously.



FIG. 17 depicts an isometric view of implant 600 inserted between vertebra 712 and vertebra 714 as well as an enlarged view of superior surface 675. It may be appreciated that, BGPM 700 is not visible in the enlarged view in FIG. 17. This is done for clarity so that new bone growth can be clearly seen as it forms along the surface of structural members of implant 600.


In FIG. 18, new bone growth occurs in multiple locations on superior surface 675. Specifically, new bone growth region 802 occurs within central cavity 671, as described above and depicted in FIGS. 14-16. In addition, new bone growth regions 804 may first form at the protected fusion zones discussed earlier. As disclosed in The Protected Fusion Zone Application, new bone growth regions 804 occurring in protected fusion zones may be protected from local forces between bone contacting members and the vertebrae. This helps minimize the disturbance to new bone growth regions 804 in the protected fusion zones.


As shown in FIG. 19, eventually, new bone growth may extend from the protective fusion zones to the entire length of plurality of bone contacting members 630. In some embodiments, new bone growth may continue to grow along the surfaces of plurality of support members 632 as well.


It may be appreciated that new bone growth similarly occurs on the inferior surface of implant 600, as well as extending around the lateral, posterior and anterior sides.


Finally, as seen in FIG. 20, new bone growth region 802 may cover the exterior, and fill the interior, of an implant. At this point, there may be a new bone fusion portion 810 that extends between vertebra 712 and vertebra 714 that fuses the vertebrae together.


In some other embodiments, increased volume for bone graft material and eventually new bone growth may be created by removing one or more structures that are disposed within an internal region of an implant. For example, in another embodiment, the structures connecting superior and inferior rings (e.g., first support 226 and second support 228 shown in FIG. 3) could be removed. Still other modifications could be made to incorporate any of the structures and/or arrangements as disclosed in U.S. Pat. No. 10,213,317, issued on Feb. 26, 2019, and titled “Implant with Supported Helical Members,” which is hereby incorporated by reference in its entirety.


Embodiments can include provisions for texturing one or more surfaces of an implant. Such texturing can increase or otherwise promote bone growth and/or fusion to surfaces of the implant. In some embodiments, bone contacting members may be textured while support members may not be textured. This helps initial bone growth to be directed along the bone contacting members and especially into the protected fusion zones, rather than growing initially across support members. In other embodiments, however, support members could include surface texturing. In still further embodiments, one or more surfaces of a body could include surface texturing.


In some embodiments, the surface structure of one or more regions of an implant may be roughened or provided with irregularities. Generally, this roughened structure may be accomplished through the use of acid etching, bead or grit blasting, sputter coating with titanium, sintering beads of titanium or cobalt chrome onto the implant surface, as well as other methods. In some embodiments, the roughness can be created by 3D printing a raised pattern on the surface of one or more regions of an implant. In some embodiments, the resulting roughened surface may have pores of varying sizes. In some embodiments, pore sizes could range between approximately 0.2 mm and 0.8 mm. In one embodiment, pore sizes could be approximately 0.5 mm. In other embodiments, surface roughness comprising pore sizes less than 0.2 mm and/or greater than 0.8 mm are possible.


The embodiments can make use of the surface texturing parts, features, processes or methods as disclosed in The Protected Fusion Zone Application.


The implants for use in the spine have overall dimensions suitable for insertion in the spine, typically between two vertebral bodies. The shape of the implant and dimensions depends on the site into which it is inserted. Exemplary heights for implants such as implant 100 and implant 600 include, but are not limited to, 5 mm to 30 mm. Other embodiments could have incremental heights of any value in the range between the aforementioned range, most often between 8 mm and 16 mm. Still other embodiments could have a height greater than 16 mm. Still other embodiments could have a height less than 8 mm. Additionally, the horizontal footprint of the implant could vary. Exemplary footprint sizes for any embodiments of the implant include, but are not limited to, 15-20 mm in the anterior-posterior direction and 40-60 mm in the lateral-lateral direction. Still other embodiments could be configured with any other footprint sizes.


The dimensions of one or more structural members could vary. In some embodiments, a structural member could have a cross-sectional diameter in a range between 0.2 and 3 mm. For structural members with polygonal cross sections, the dimensions characterizing the polygon (e.g., first and second diameters for an ellipse) could vary. As an example, a structural member with an elliptic cross section could have a cross section with a first diameter in a range between 0.2 mm and 3 mm and a second diameter in range between 0.2 mm and 3 mm. In other embodiments, a structural member could have any other cross-sectional diameter. Moreover, in some cases a bone contacting member and a support member could have similar cross-sectional diameters while in other cases a bone contacting member and a support member could have different cross-sectional diameters.


Embodiments can also be provided with various flat/parallel (0-degree), lordotic, and hyper-lordotic angles. In some embodiments, the implant can be configured with an approximately 8-degree angle between the superior and inferior surfaces. In other embodiments, the implant can be configured with an approximately 15-degree angle between the superior and inferior surfaces. In still other embodiments, the implant can be configured with an approximately 20-degree angle between the superior and inferior surfaces. Still other angles are possibly including any angles in the range between 0 and 30 degrees. Still other embodiments can provide a lordotic angle of less than 8 degrees. Still other embodiments can provide a hyper-lordotic angle of more than 20 degrees. In at least some embodiments, the lordotic angle of the implant is accomplished via the geometry of the central keel portion and the side frame portion (posterior or anterior).


The various components of an implant may be fabricated from biocompatible materials suitable for implantation in a human body, including but not limited to, metals (e.g. titanium or other metals), synthetic polymers, ceramics, and/or their combinations, depending on the particular application and/or preference of a medical practitioner.


Generally, the implant can be formed from any suitable biocompatible, non-degradable material with sufficient strength. Typical materials include, but are not limited to, titanium, biocompatible titanium alloys (e.g. γTitanium Aluminides, Ti6-Al4-V ELI (ASTM F 136 and F 3001), or Ti6-Al4-V (ASTM F 2989, F 1108 and ASTM F 1472)) and inert, biocompatible polymers, such as polyether ether ketone (PEEK) (e.g. PEEK-OPTIMA®, Invibio Inc and Zeniva Solvay Inc.). Optionally, the implant contains a radiopaque marker to facilitate visualization during imaging.


In different embodiments, processes for making an implant can vary. In some embodiments, the entire implant may be manufactured and assembled via readditional/CNC machining, injection-molding, casting, insert-molding, co-extrusion, pultrusion, transfer molding, overmolding, compression molding, 3-Dimensional (3-D) printing (including Direct Metal Laser Sintering and Electron Beam Melting), dip-coating, spray-coating, powder-coating, porous-coating, milling from a solid stock material and their combinations. Moreover, the embodiments can make use of any of the features, parts, assemblies, processes and/or methods disclosed in the “The Coiled Implant Application”.


While various embodiments have been described, the description is intended to be exemplary, rather than limiting, and it will be apparent to those of ordinary skill in the art that many more embodiments and implementations are possible that are within the scope of the embodiments. Although many possible combinations of features are shown in the accompanying figures and discussed in this detailed description, many other combinations of the disclosed features are possible. Any feature of any embodiment may be used in combination with or substituted for any other feature or element in any other embodiment unless specifically restricted. Therefore, it will be understood that any of the features shown and/or discussed in the present disclosure may be implemented together in any suitable combination. Accordingly, the embodiments are not to be restricted except in light of the attached claims and their equivalents. Also, various modifications and changes may be made within the scope of the attached claims.

Claims
  • 1. An implant, comprising: a body including a ring, the ring further defining an opening;the body defining a transverse plane dividing the implant into a superior half and an inferior half;the ring defining a radial direction and a circumferential direction;a first outer member attached to the ring, wherein the first outer member extends radially from the ring;wherein the first outer member defines one or more arches; andwherein the ring further defines a central channel extending through the implant.
  • 2. The implant according to claim 1, wherein the central channel extends from a superior side to an inferior side of the implant.
  • 3. The implant according to claim 1, wherein the one or more arches of the first outer member extend in a superior direction.
  • 4. The implant according to claim 1, wherein the body includes a peripheral frame portion that defines an outer periphery of the implant; and wherein the first outer member extends from the ring to the peripheral frame portion.
  • 5. The implant according to claim 1, wherein the first outer member has a generally helical geometry defining a plurality of arches.
  • 6. The implant according to claim 5, wherein the implant further includes a second outer member, a third outer member, and a fourth outer member.
  • 7. The implant according to claim 6, wherein the first outer member and the second outer member extend from a first side of the ring to a first end of the implant, and wherein the third outer member and the fourth outer member extend from a second side of the ring to a second end of the implant.
  • 8. The implant according to claim 7, wherein the implant further includes a plurality of supports, wherein each of the plurality of supports are attached to at least one outer member, and wherein each of the plurality of supports extend in the circumferential direction.
  • 9. The implant according to claim 8, wherein the first outer member, the second outer member, the third outer member, the fourth outer member and the plurality of supports are arranged in a web-like pattern.
  • 10. The implant according to claim 9, wherein the web-like pattern is disposed in the superior half of the implant, and wherein the implant has another web-like pattern formed of outer members and supports disposed in the inferior half of the implant.
  • 11. The implant according to claim 1, further including a support attached to the first outer member at an attachment region, wherein the support extends in the circumferential direction.
  • 12. The implant according to claim 11, wherein, at the attachment region, the support is disposed closer to the transverse plane than the first outer member is to the transverse plane.
  • 13. An implant, comprising: a body;the body defining a transverse plane dividing the implant into a superior half and an inferior half;a first outer member attached to the body and disposed within the superior half of the implant;a first support attached to the first outer member, the first support being disposed within the superior half of the implant;a second outer member attached to the body and disposed within the inferior half of the implant;a second support attached to the second outer member, the second support being disposed within the inferior half of the implant;wherein an end of the first support is attached to an end of the second support; andwherein the first outer member and the second outer member each form one or more arches;wherein the implant includes a first ring disposed in the superior half, wherein the first outer member is attached to the first ring;the implant includes a second ring disposed in the inferior half, wherein the second outer member is attached to the second ring;wherein the first ring and the second ring define a central channel extending through the implant.
  • 14. The implant according to claim 13, wherein the first ring is joined to the second ring by additional supports extending through the transverse plane, such that the first ring and the second ring define openings for the central channel extending through the implant.
  • 15. The implant according to claim 13, wherein the central channel extends from a superior side to an inferior side of the implant.
  • 16. The implant according to claim 13, wherein the one or more arches of the first outer member extend in a superior direction.
  • 17. An implant, comprising: a body;the body defining a transverse plane dividing the implant into a superior half and an inferior half;a plurality of outer members disposed within the superior half of the implant and extending from a central region of the body to a periphery of the body; andwherein each of the outer members in the plurality of outer members extend radially away from the central region of the body;wherein each of the plurality of outer members form one or more arches; andwherein the implant includes at least one ring disposed in the central region of the body and defining a central channel extending through the implant from a superior side to an inferior side of the body.
  • 18. The implant according to claim 17, wherein the implant includes three or more outer members.
  • 19. The implant according to claim 17, wherein the body includes a peripheral frame portion that defines an outer periphery of the implant; and wherein the outer members extend from the at least one ring to the peripheral frame portion.
  • 20. The implant according to claim 17, wherein the implant further includes a plurality of supports, wherein each of the plurality of supports are attached to at least one outer member, and wherein each of the plurality of supports extend in a circumferential direction defined by the at least one ring.
US Referenced Citations (572)
Number Name Date Kind
3720959 Hahn Mar 1973 A
4038703 Bokros Aug 1977 A
4309777 Patil Jan 1982 A
4759769 Hedman Jul 1988 A
4851008 Johnson Jul 1989 A
4889685 Shimamune Dec 1989 A
4917704 Frey Apr 1990 A
4961740 Ray et al. Oct 1990 A
5055104 Ray Oct 1991 A
5059193 Kuslich Oct 1991 A
5198308 Shetty et al. Mar 1993 A
5263953 Bagby Nov 1993 A
5306310 Siebels Apr 1994 A
5397359 Mittelmeier Mar 1995 A
5423817 Lin Jun 1995 A
5458638 Kuslich et al. Oct 1995 A
5571185 Schug Nov 1996 A
5571192 Schonhoffer Nov 1996 A
5607424 Tropiano Mar 1997 A
5609635 Michelson Mar 1997 A
5609636 Kohrs Mar 1997 A
5658337 Kohrs et al. Aug 1997 A
5709683 Bagby Jan 1998 A
5716416 Lin Feb 1998 A
D403069 Drewry et al. Dec 1998 S
5885299 Winslow Mar 1999 A
5888223 Bray, Jr. Mar 1999 A
5897556 Drewry et al. Apr 1999 A
5954504 Misch et al. Sep 1999 A
5968098 Winslow Oct 1999 A
5973222 Devanathan et al. Oct 1999 A
6010502 Bagby Jan 2000 A
6039762 McKay Mar 2000 A
6090143 Meriwether et al. Jul 2000 A
6102948 Brosnahan, III Aug 2000 A
6126689 Brett Oct 2000 A
6149651 Drewry et al. Nov 2000 A
6156037 LeHuec et al. Dec 2000 A
6200348 Biedermann et al. Mar 2001 B1
6206924 Timm Mar 2001 B1
6210412 Michelson Apr 2001 B1
6371987 Weiland et al. Apr 2002 B1
6428575 Koo et al. Aug 2002 B2
6436141 Castro et al. Aug 2002 B2
6464727 Sharkey Oct 2002 B1
6468309 Lieberman Oct 2002 B1
6494883 Ferree Dec 2002 B1
6500205 Michelson Dec 2002 B1
6520996 Manasas et al. Feb 2003 B1
6527805 Studer et al. Mar 2003 B2
6530956 Mansmann Mar 2003 B1
6537320 Michelson Mar 2003 B1
6558423 Michelson May 2003 B1
6569201 Moumene May 2003 B2
6582431 Ray Jun 2003 B1
6582467 Teitelbaum et al. Jun 2003 B1
6585770 White et al. Jul 2003 B1
6616695 Crozet et al. Sep 2003 B1
6666888 Jackson Dec 2003 B1
6709458 Michelson Mar 2004 B2
6758849 Michelson Jul 2004 B1
6808537 Michelson Oct 2004 B2
6846327 Khandkar et al. Jan 2005 B2
6849093 Michelson Feb 2005 B2
6863689 Ralph et al. Mar 2005 B2
6923810 Michelson Aug 2005 B1
6962606 Michelson Nov 2005 B2
6997953 Chung et al. Feb 2006 B2
7135043 Nakahara et al. Nov 2006 B2
7141068 Ross et al. Nov 2006 B2
7153325 Kim et al. Dec 2006 B2
7186267 Aston et al. Mar 2007 B2
7241313 Unwin et al. Jul 2007 B2
7261739 Ralph Aug 2007 B2
7297162 Mujwid Nov 2007 B2
7341601 Eisermann et al. Mar 2008 B2
7410501 Michelson Aug 2008 B2
7429270 Baumgartner et al. Sep 2008 B2
7435261 Castro Oct 2008 B1
7452369 Barry Nov 2008 B2
7465318 Sennett et al. Dec 2008 B2
7485134 Simonson Feb 2009 B2
7527649 Blain May 2009 B1
7534254 Michelson May 2009 B1
7537603 Huebner et al. May 2009 B2
7537616 Branch et al. May 2009 B1
7575598 Albert Aug 2009 B2
7611217 Shamoun et al. Nov 2009 B2
7621952 Truckai et al. Nov 2009 B2
7621953 Braddock, Jr. et al. Nov 2009 B2
7628814 Studer et al. Dec 2009 B2
7645475 Prewett Jan 2010 B2
7655043 Peterman et al. Feb 2010 B2
7794500 Felix Sep 2010 B2
7799056 Sankaran Sep 2010 B2
7803191 Biedermann et al. Sep 2010 B2
7815665 Jahng Oct 2010 B2
7846207 Lechmann et al. Dec 2010 B2
7875075 Schwab Jan 2011 B2
7879100 Denoziere Feb 2011 B2
7879103 Gertzman et al. Feb 2011 B2
7935149 Michelson May 2011 B2
8016887 Castro Sep 2011 B1
8021424 Beger et al. Sep 2011 B2
8021426 Segal et al. Sep 2011 B2
8062365 Schwab Nov 2011 B2
8092536 Ahrens et al. Jan 2012 B2
8142507 McGuckin, Jr. Mar 2012 B2
8152849 Biedermann et al. Apr 2012 B2
8182538 O'Neil et al. May 2012 B2
8226718 Castro Jul 2012 B2
8241363 Sommerich et al. Aug 2012 B2
8246683 Castro Aug 2012 B2
8252059 Overes et al. Aug 2012 B2
8298286 Trieu Oct 2012 B2
8303879 Bertele et al. Nov 2012 B2
8343224 Lynn Jan 2013 B2
8361149 Castro Jan 2013 B2
8366777 Matthis et al. Feb 2013 B2
D681204 Farris et al. Apr 2013 S
8414654 Ganey Apr 2013 B1
8414820 Bertele et al. Apr 2013 B2
8430930 Hunt Apr 2013 B2
D681812 Farris et al. May 2013 S
8435300 Messerli et al. May 2013 B2
8454700 Lemoine et al. Jun 2013 B2
8475533 Castro Jul 2013 B1
8529628 Marino et al. Sep 2013 B2
8551173 Lechmann et al. Oct 2013 B2
8556978 Schaller Oct 2013 B2
8568413 Mazur et al. Oct 2013 B2
8613769 Sears et al. Dec 2013 B2
8623090 Butler Jan 2014 B2
8673006 Castro Mar 2014 B2
8700198 Conway et al. Apr 2014 B2
8702808 Teoh et al. Apr 2014 B2
8709042 Greenhalgh et al. Apr 2014 B2
8728160 Globerman May 2014 B2
8740981 Tornier et al. Jun 2014 B2
8771357 Biedermann et al. Jul 2014 B2
8771368 McKay Jul 2014 B2
8795362 Anderson et al. Aug 2014 B2
8801787 Schaller Aug 2014 B2
8808376 Schaller Aug 2014 B2
8808725 Altschuler et al. Aug 2014 B2
8840614 Mikhail et al. Sep 2014 B2
8864831 Lee et al. Oct 2014 B2
8894661 McDevitt Nov 2014 B2
8900310 Carlson Dec 2014 B2
8900312 McLean et al. Dec 2014 B2
8932356 Kraus Jan 2015 B2
8940050 Laurence Jan 2015 B2
8940052 Lechmann et al. Jan 2015 B2
8951300 Parrish Feb 2015 B2
8986383 Castro Mar 2015 B2
9011499 Kiester Apr 2015 B1
9039766 Fonte May 2015 B1
9060876 To Jun 2015 B1
9101491 Rodgers Aug 2015 B2
D739935 Blain et al. Sep 2015 S
9138301 Kita et al. Sep 2015 B2
9155819 Fonte et al. Oct 2015 B2
9186252 Leibinger Nov 2015 B2
9186257 Geisler Nov 2015 B2
9220518 Neal et al. Dec 2015 B2
9237958 Duggal et al. Jan 2016 B2
9247970 Teisen Feb 2016 B2
9254199 Biedermann et al. Feb 2016 B2
9271765 Blain Mar 2016 B2
9271771 Mathieu et al. Mar 2016 B2
9271845 Hunt et al. Mar 2016 B2
9289308 Marino et al. Mar 2016 B2
9289312 Davenport et al. Mar 2016 B2
9295562 Lechmann et al. Mar 2016 B2
9364330 Lindsey et al. Jun 2016 B2
9364339 Mayer Jun 2016 B2
9402733 To et al. Aug 2016 B1
9408651 Sennett et al. Aug 2016 B2
9421108 Hunt Aug 2016 B2
9427328 Drochner Aug 2016 B2
9433510 Lechmann et al. Sep 2016 B2
9433511 Bagga et al. Sep 2016 B2
9439779 Zhang et al. Sep 2016 B2
9439948 Lin et al. Sep 2016 B2
9452056 Early et al. Sep 2016 B2
9452064 Trautwein et al. Sep 2016 B2
9456901 Jones et al. Oct 2016 B2
9456907 Castro Oct 2016 B1
9517095 Vaidya Dec 2016 B2
9522028 Warren et al. Dec 2016 B2
9526548 Asfora Dec 2016 B2
9545317 Hunt Jan 2017 B2
9549823 Hunt et al. Jan 2017 B2
9554914 Taylor et al. Jan 2017 B2
9561117 Lechmann et al. Feb 2017 B2
9566095 Lorio Feb 2017 B2
9566100 Asfora Feb 2017 B2
9572669 Hunt et al. Feb 2017 B2
9597197 Lechmann et al. Mar 2017 B2
9603613 Schoenefeld et al. Mar 2017 B2
9622880 Dunworth et al. Apr 2017 B2
9629727 Baynham Apr 2017 B2
9636226 Hunt May 2017 B2
9649200 Wickham May 2017 B2
9662128 Reiley May 2017 B2
9662157 Schneider et al. May 2017 B2
9662158 Reiley May 2017 B2
9662224 Weiman et al. May 2017 B2
9662226 Wickham May 2017 B2
9668781 Stark Jun 2017 B2
9675394 Reiley Jun 2017 B2
9700356 Donner et al. Jul 2017 B2
9744051 Biedermann et al. Aug 2017 B2
9757235 Hunt et al. Sep 2017 B2
9782270 Wickham Oct 2017 B2
9788967 Jo Oct 2017 B2
9814578 Gotfried Nov 2017 B1
9907670 DeRidder et al. Mar 2018 B2
9918849 Morris Mar 2018 B2
9931209 Gotfried Apr 2018 B2
9987051 Nunley et al. Jun 2018 B2
9987137 Hunt et al. Jun 2018 B2
9999516 Hunt Jun 2018 B2
10004546 Gotfried Jun 2018 B2
10016279 Castro Jul 2018 B1
10058433 Lechmann et al. Aug 2018 B2
10064737 Tsai et al. Sep 2018 B2
10098754 Larsson Oct 2018 B2
10117746 Cordaro Nov 2018 B2
10143569 Weiman et al. Dec 2018 B2
10154913 Steinmann et al. Dec 2018 B2
10159580 Guizzardi et al. Dec 2018 B2
10182923 Willis et al. Jan 2019 B2
10194962 Schneider et al. Feb 2019 B2
10195524 DeRidder et al. Feb 2019 B2
10213317 Bishop et al. Feb 2019 B2
10226357 Ries Mar 2019 B2
10265189 Melkent et al. Apr 2019 B2
10271958 Schaufler et al. Apr 2019 B2
10278833 Howard et al. May 2019 B2
10278834 Howard et al. May 2019 B2
10357377 Nyahay et al. Jul 2019 B2
10368997 Jones et al. Aug 2019 B2
10369009 Joly et al. Aug 2019 B2
10413427 Trieu Sep 2019 B2
10433977 Lechmann et al. Oct 2019 B2
10433979 Morris et al. Oct 2019 B2
10449051 Hamzey et al. Oct 2019 B2
10449055 McJunkin Oct 2019 B2
10449058 Lechmann et al. Oct 2019 B2
10478312 McShane, III et al. Nov 2019 B2
D870288 Dang et al. Dec 2019 S
10492921 McShane, III et al. Dec 2019 B2
10507118 Afzal Dec 2019 B2
10512549 Bishop Dec 2019 B2
10517739 Ryan Dec 2019 B2
10524926 Jasinski Jan 2020 B2
10524927 Ryan Jan 2020 B2
10524929 Shoshtaev Jan 2020 B2
10525688 O'Neill et al. Jan 2020 B2
10531962 Petersheim et al. Jan 2020 B2
10537666 Paddock et al. Jan 2020 B2
10555819 Miccio Feb 2020 B2
10561456 Cawley et al. Feb 2020 B2
10575965 Kim et al. Mar 2020 B2
10588755 Vogt et al. Mar 2020 B2
10617532 Mazur et al. Apr 2020 B2
10624760 Mirda et al. Apr 2020 B2
10660763 Wilson et al. May 2020 B2
10660764 Maglaras et al. May 2020 B2
10667924 Nyahay et al. Jun 2020 B2
10675158 Unger et al. Jun 2020 B2
10675385 Barbas et al. Jun 2020 B2
10682238 Petersheim et al. Jun 2020 B2
10695192 Bishop et al. Jun 2020 B2
10709570 Stauffer et al. Jul 2020 B2
10716678 Stampfli et al. Jul 2020 B2
10722378 Davis et al. Jul 2020 B2
10744001 Sack Aug 2020 B2
10744003 Ryan et al. Aug 2020 B2
10765530 Steinmann et al. Sep 2020 B2
10772732 Miller et al. Sep 2020 B1
D898197 Cain Oct 2020 S
10835388 Milz et al. Nov 2020 B2
10849756 Hunt et al. Dec 2020 B2
10856999 Bishop et al. Dec 2020 B2
10940019 Vishnubhotla et al. Mar 2021 B2
D920515 Miller et al. May 2021 S
D920516 Miller et al. May 2021 S
11026798 Miller et al. Jun 2021 B1
11033394 Hamzey et al. Jun 2021 B2
11065039 McCormack Jul 2021 B2
11147679 Kowalczyk et al. Oct 2021 B2
11160668 Nyahay et al. Nov 2021 B2
D942011 Cain Jan 2022 S
11213405 Bishop Jan 2022 B2
D942623 Cain Feb 2022 S
D942624 Cain Feb 2022 S
D944400 Cain Feb 2022 S
11273048 Cain et al. Mar 2022 B2
11452611 McShane, III et al. Sep 2022 B2
20010014826 Biedermann et al. Aug 2001 A1
20010032018 Castro et al. Oct 2001 A1
20020052656 Michelson May 2002 A1
20020120334 Crozet Aug 2002 A1
20020123750 Eisermann et al. Sep 2002 A1
20020183847 Lieberman Dec 2002 A1
20030003127 Brown et al. Jan 2003 A1
20030060825 Alfaro Mar 2003 A1
20030078660 Clifford et al. Apr 2003 A1
20030083746 Kuslich May 2003 A1
20030109928 Pasquet Jun 2003 A1
20030181913 Lieberman Sep 2003 A1
20030236571 Ralph Dec 2003 A1
20040059419 Michelson Mar 2004 A1
20040082953 Petit Apr 2004 A1
20040122518 Rhoda Jun 2004 A1
20040193270 DiMauro et al. Sep 2004 A1
20040210312 Neumann Oct 2004 A1
20040225361 Glenn et al. Nov 2004 A1
20040243129 Moumene Dec 2004 A1
20050015154 Lindsey et al. Jan 2005 A1
20050027364 Kim Feb 2005 A1
20050143733 Petit Jun 2005 A1
20050177238 Khandkar et al. Aug 2005 A1
20050187627 Ralph Aug 2005 A1
20050222681 Richley et al. Oct 2005 A1
20050278027 Hyde, Jr. Dec 2005 A1
20050278028 Mujwid Dec 2005 A1
20060041262 Calvert et al. Feb 2006 A1
20060052872 Studer Mar 2006 A1
20060052873 Buck Mar 2006 A1
20060058881 Trieu Mar 2006 A1
20060100706 Shadduck et al. May 2006 A1
20060147332 Jones et al. Jul 2006 A1
20060212118 Abernathie Sep 2006 A1
20060217806 Peterman Sep 2006 A1
20060293753 Thramann Dec 2006 A1
20070027544 McCord et al. Feb 2007 A1
20070179610 Biedermann et al. Aug 2007 A1
20070198090 Abdou Aug 2007 A1
20070260324 Joshi et al. Nov 2007 A1
20080071356 Greenhalgh Mar 2008 A1
20080167686 Trieu Jul 2008 A1
20080183204 Greenhalgh et al. Jul 2008 A1
20080255666 Fisher Oct 2008 A1
20080288083 Axelsson et al. Nov 2008 A1
20080300602 Schmitt et al. Dec 2008 A1
20080306595 McLeod et al. Dec 2008 A1
20080312742 Abernathie Dec 2008 A1
20090030520 Biedermann Jan 2009 A1
20090036985 Whiting Feb 2009 A1
20090048675 Bhatnagar et al. Feb 2009 A1
20090048678 Saal et al. Feb 2009 A1
20090062917 Foley et al. Mar 2009 A1
20090112321 Kitchen Apr 2009 A1
20090149958 Prewett et al. Jun 2009 A1
20090248162 Peckham Oct 2009 A1
20100016974 Janowski Jan 2010 A1
20100036498 McDevitt Feb 2010 A1
20100057216 Gannoe et al. Mar 2010 A1
20100137990 Apatsidis Jun 2010 A1
20100152856 Overes Jun 2010 A1
20100161061 Hunt Jun 2010 A1
20100185292 Hochschuler Jul 2010 A1
20100228299 Zrinski et al. Sep 2010 A1
20100286778 Eisermann et al. Nov 2010 A1
20110015741 Melkent et al. Jan 2011 A1
20110029085 Hynes Feb 2011 A1
20110035019 Goswami et al. Feb 2011 A1
20110066192 Frasier et al. Mar 2011 A1
20110166660 Laurence Jul 2011 A1
20110190888 Bertele Aug 2011 A1
20110190895 Segal et al. Aug 2011 A1
20110208311 Janowski Aug 2011 A1
20110230970 Lynn Sep 2011 A1
20110245926 Kitchen Oct 2011 A1
20110270401 McKay Nov 2011 A1
20110301709 Kraus et al. Dec 2011 A1
20110313528 Laubert Dec 2011 A1
20110313532 Hunt Dec 2011 A1
20120010472 Spann Jan 2012 A1
20120010717 Spann Jan 2012 A1
20120150300 Nihalani Jun 2012 A1
20120158143 Shapiro Jun 2012 A1
20120191188 Huang Jul 2012 A1
20120191189 Huang Jul 2012 A1
20120239150 Ullrich Sep 2012 A1
20120296431 Kim Nov 2012 A1
20130030529 Hunt Jan 2013 A1
20130096685 Ciupik Apr 2013 A1
20130116793 Kloss May 2013 A1
20130123935 Hunt et al. May 2013 A1
20130158672 Hunt Jun 2013 A1
20130184826 Thaiyananthan Jul 2013 A1
20130190880 Schaller Jul 2013 A1
20130021288 Fonte Aug 2013 A1
20130204374 Milella, Jr. Aug 2013 A1
20130218282 Hunt Aug 2013 A1
20130218288 Fonte Aug 2013 A1
20130226300 Chataigner Aug 2013 A1
20130304211 Trautwein et al. Nov 2013 A1
20130325129 Huang Dec 2013 A1
20140018814 Gillard et al. Jan 2014 A1
20140052260 McKenny Feb 2014 A1
20140058513 Gahman et al. Feb 2014 A1
20140107785 Geisler Apr 2014 A1
20140107786 Geisler Apr 2014 A1
20140114418 Landry Apr 2014 A1
20140121776 Hunt May 2014 A1
20140142707 Compton et al. May 2014 A1
20140172111 Lang et al. Jun 2014 A1
20140195005 McKay Jul 2014 A1
20140228956 Weiman Aug 2014 A1
20140228960 Forterre Aug 2014 A1
20140243980 Sack et al. Aug 2014 A1
20140249631 Weiman Sep 2014 A1
20140277457 Yeung et al. Sep 2014 A1
20140277464 Richter et al. Sep 2014 A1
20140277569 Lange Sep 2014 A1
20140288649 Hunt Sep 2014 A1
20140288650 Hunt Sep 2014 A1
20140303736 Roussouly Oct 2014 A1
20140303745 Anderson et al. Oct 2014 A1
20140309743 Falahee Oct 2014 A1
20140336771 Zambiasi Nov 2014 A1
20140358246 Levy et al. Dec 2014 A1
20150045903 Neal Feb 2015 A1
20150112351 Hsu Apr 2015 A1
20150127106 Partee May 2015 A1
20150173910 Siegal Jun 2015 A1
20150223951 Bae et al. Aug 2015 A1
20150282944 Guizzardi et al. Oct 2015 A1
20150359635 Kita et al. Dec 2015 A1
20160015437 Elleby et al. Jan 2016 A1
20160022430 Wickham Jan 2016 A1
20160081809 Schneider et al. Mar 2016 A1
20160166284 Hacking et al. Jun 2016 A1
20160184103 Fonte et al. Jun 2016 A1
20160193057 Rhoda Jul 2016 A1
20160206439 To et al. Jul 2016 A1
20160206440 DeRidder et al. Jul 2016 A1
20160262903 West Sep 2016 A1
20160270920 Dawson et al. Sep 2016 A1
20160287388 Hunt et al. Oct 2016 A1
20160310294 McConnell et al. Oct 2016 A1
20160317320 Ahn Nov 2016 A1
20160324656 Morris Nov 2016 A1
20160374727 Greenhalgh et al. Dec 2016 A1
20170007409 Mauldin et al. Jan 2017 A1
20170014235 Jones et al. Jan 2017 A1
20170020685 Geisler et al. Jan 2017 A1
20170042697 McShane, III Feb 2017 A1
20170049488 Vestgaarden Feb 2017 A1
20170095337 Pasini et al. Apr 2017 A1
20170095352 Bruffey Apr 2017 A1
20170100167 Lange et al. Apr 2017 A1
20170135706 Frey et al. May 2017 A1
20170135733 Donner et al. May 2017 A1
20170143383 Ingalhalikar et al. May 2017 A1
20170151005 Warren et al. Jun 2017 A1
20170156740 Stark Jun 2017 A9
20170156766 Anderson et al. Jun 2017 A1
20170156878 Tsai Jun 2017 A1
20170156879 Janowski Jun 2017 A1
20170156880 Halverson et al. Jun 2017 A1
20170164979 Donner et al. Jun 2017 A1
20170181784 Li Jun 2017 A1
20170182222 Paddock Jun 2017 A1
20170196693 Jurick et al. Jul 2017 A1
20170216034 Daniel Aug 2017 A1
20170216035 Hunt Aug 2017 A1
20170239064 Cordaro Aug 2017 A1
20170239066 Walsh et al. Aug 2017 A1
20170258606 Afzal Sep 2017 A1
20170319353 Greenhalgh et al. Nov 2017 A1
20170348107 Lee et al. Dec 2017 A1
20170348115 Greenhalgh Dec 2017 A1
20180064540 Hunt et al. Mar 2018 A1
20180085230 Hunt Mar 2018 A1
20180110626 McShane, III Apr 2018 A1
20180161477 Nies Jun 2018 A1
20180221156 Jones Aug 2018 A1
20180243104 Garonzik Aug 2018 A1
20180256336 Mueller et al. Sep 2018 A1
20180256351 Bishop Sep 2018 A1
20180256352 Nyahay Sep 2018 A1
20180256353 Nyahay Sep 2018 A1
20180280139 Jones Oct 2018 A1
20180289503 Knapp Oct 2018 A1
20180296343 Wei Oct 2018 A1
20180296347 Hamzey Oct 2018 A1
20180326493 Gallagher et al. Nov 2018 A1
20180333272 Mirda Nov 2018 A1
20180338838 Cryder Nov 2018 A1
20180368981 Mattes et al. Dec 2018 A1
20180368991 Levieux Dec 2018 A1
20190000636 Kim et al. Jan 2019 A1
20190015209 Seifert et al. Jan 2019 A1
20190038428 Stauffer Feb 2019 A1
20190060079 Unis et al. Feb 2019 A1
20190060083 Weiman et al. Feb 2019 A1
20190076266 Trudeau et al. Mar 2019 A1
20190083282 Roeder et al. Mar 2019 A1
20190091027 Asaad et al. Mar 2019 A1
20190133769 Tetsworth et al. May 2019 A1
20190151109 Amin May 2019 A1
20190151113 Sack May 2019 A1
20190159818 Schneider et al. May 2019 A1
20190183653 Gregersen et al. Jun 2019 A1
20190224023 Howard et al. Jul 2019 A1
20190254840 Gray et al. Aug 2019 A1
20190262139 Wolters Aug 2019 A1
20190274841 Hawkes et al. Sep 2019 A1
20190298542 Kloss Oct 2019 A1
20190307574 Nyahay et al. Oct 2019 A1
20190314169 Patel et al. Oct 2019 A1
20190328546 Palagi et al. Oct 2019 A1
20190336305 Joly et al. Nov 2019 A1
20190343645 Miccio et al. Nov 2019 A1
20190358058 Trieu Nov 2019 A1
20190388238 Lechmann et al. Dec 2019 A1
20200000603 McJunkin Jan 2020 A1
20200036011 Numata et al. Jan 2020 A1
20200038197 Morris et al. Feb 2020 A1
20200038198 Miccio Feb 2020 A1
20200086625 O'Neill et al. Mar 2020 A1
20200113707 Petersheim et al. Apr 2020 A1
20200113709 Hsieh Apr 2020 A1
20200121470 Moore et al. Apr 2020 A1
20200138595 Shoshtaev et al. May 2020 A1
20200146842 Jasinski May 2020 A1
20200155326 Hunt May 2020 A1
20200179128 Stalcup et al. Jun 2020 A1
20200179133 Ryan Jun 2020 A1
20200188120 Hamzey et al. Jun 2020 A1
20200188129 McShane, III et al. Jun 2020 A1
20200188132 Ryan Jun 2020 A1
20200188133 McShane, III et al. Jun 2020 A1
20200190680 Numata et al. Jun 2020 A1
20200197189 Mazur et al. Jun 2020 A1
20200214852 Tipping et al. Jul 2020 A1
20200222201 Mirda et al. Jul 2020 A1
20200229940 Bishop Jul 2020 A1
20200229945 Levieux Jul 2020 A1
20200237526 Wilson et al. Jul 2020 A1
20200246160 Zappacosta et al. Aug 2020 A1
20200261243 Unger et al. Aug 2020 A1
20200268523 Barthold et al. Aug 2020 A1
20200276019 Shetty et al. Sep 2020 A1
20200281727 Dang et al. Sep 2020 A1
20200297494 Hunt et al. Sep 2020 A1
20200297505 McLaughlin Sep 2020 A1
20200315812 Davis et al. Oct 2020 A1
20200323645 Northcutt et al. Oct 2020 A1
20200337851 Stampfli et al. Oct 2020 A1
20200337855 Stauffer et al. Oct 2020 A1
20200337856 Moore et al. Oct 2020 A1
20200345506 Rayan et al. Nov 2020 A1
20200352735 Afzal Nov 2020 A1
20200375757 Sack Dec 2020 A1
20200375758 Northcutt et al. Dec 2020 A1
20200376174 Melkent et al. Dec 2020 A1
20210022882 Dang et al. Jan 2021 A1
20210046211 Deisinger et al. Feb 2021 A1
20210069383 Yamaguchi et al. Mar 2021 A1
20210085481 Cain et al. Mar 2021 A1
20210307909 Hamzey et al. Oct 2021 A1
20220047398 Nyahay et al. Feb 2022 A1
20220071777 Cain et al. Mar 2022 A1
20220117751 Bishop Apr 2022 A1
20220117753 Rucker et al. Apr 2022 A1
Foreign Referenced Citations (62)
Number Date Country
101708138 May 2010 CN
103932841 Jul 2014 CN
204931903 Jan 2016 CN
110179570 Aug 2021 CN
19722389 Dec 1998 DE
3064175 Sep 2016 EP
3494931 Jun 2019 EP
3517078 Jul 2019 EP
3603580 Feb 2020 EP
2815846 May 2002 FR
2955025 Jul 2011 FR
H05261146 Oct 1993 JP
H09503416 Sep 1997 JP
2001523129 Nov 2001 JP
20010523129 Nov 2001 JP
2004-510494 Apr 2004 JP
2006515194 May 2006 JP
2007151805 Jun 2007 JP
2009-505686 Feb 2009 JP
2009504332 Feb 2009 JP
4313005 Aug 2009 JP
2010137069 Jun 2010 JP
201115959 Jan 2011 JP
2011015959 Jan 2011 JP
2012-501236 Jan 2012 JP
2012501236 Jan 2012 JP
20120501236 Jan 2012 JP
5328051 Oct 2013 JP
5455020 Mar 2014 JP
2014-151209 Aug 2014 JP
2015-502192 Jan 2015 JP
2015502192 Jan 2015 JP
5684177 Mar 2015 JP
2015529150 Oct 2015 JP
A2018-516646 Jun 2018 JP
2019034071 Mar 2019 JP
2019041886 Mar 2019 JP
2019180797 Oct 2019 JP
2019201688 Nov 2019 JP
6700135 May 2020 JP
2020199326 Dec 2020 JP
2021016498 Feb 2021 JP
2012-501236 Jan 2012 PA
WO 9510248 Apr 1995 WO
WO 9848738 Nov 1998 WO
WO 9852498 Nov 1998 WO
WO 0209625 Feb 2002 WO
WO 0234168 May 2002 WO
WO 03099160 Dec 2003 WO
WO 2004084774 Oct 2004 WO
WO 2005011523 Feb 2005 WO
WO 2009051779 Mar 2006 WO
WO 2007022194 Feb 2007 WO
WO 2009051779 Apr 2009 WO
WO 2010028056 Mar 2010 WO
WO 2010097632 Sep 2010 WO
WO 2013067528 May 2013 WO
WO 2014052477 Apr 2014 WO
2014168631 Oct 2014 WO
WO 2016044739 Mar 2016 WO
WO 2016176496 Nov 2016 WO
WO 2017100366 Jun 2017 WO
Non-Patent Literature Citations (47)
Entry
Office Action dated May 5, 2017 in U.S. Appl. No. 15/141,655.
Office Action dated Nov. 1, 2018 in U.S. Appl. No. 15/885,418.
Final Office Action dated Feb. 25, 2019 in U.S. Appl. No. 15/885,418.
Office Action dated Nov. 2, 2021 in U.S. Appl. No. 16/593,101.
International Search Report and Written Opinion dated Aug. 19, 2016 in PCT/US2016/029865.
Office Action dated Apr. 3, 2019 in Chinese Application No. 2016800391036.
Office Action dated Jun. 28, 2019 in European Application No. 16722008.6-1132.
Extended European Search Report dated Dec. 8, 2020 in European Application No. 20191843.0-1132.
ISO/ASTM 52900:2015€ Standard Terminology for Additive Manufacturing—General Principles—Terminology, 2017.
Office Action dated Mar. 5, 2020 in Japanese Application No. 2017-556733.
Office Action dated Sep. 2, 2021 in Japanese Application No. 2020-156918.
Notice of Decision to Grant a Patent dated Jul. 7, 2022 in Japanese Application No. 2020-156918.
Office Action dated Sep. 2, 2021 in Japanese Application No. 2020-156917.
Notice of Decision to Grant a Patent dated Jul. 7, 2022 in Japanese Application No. 2020-156917.
Office Action dated May 2, 2018 in U.S. Appl. No. 15/334,975.
Office Action dated Dec. 3, 2018 in U.S. Appl. No. 15/334,053.
Office Action dated Sep. 15, 2022 in U.S. Appl. No. 16/700,632.
Final Office Action dated Jun. 2, 2023 in U.S. Appl. No. 16/700,632.
International Search Report and Written Opinion dated Jan. 18, 2018.
“FDA Clears Camber Spine Technologies' 3D Printed SPIRA Open Matrix ALIF”, Orthopedic Design & Technology, Aug. 15, 2017.
Supplemental Partial European Search Report dated May 15, 2020 in European Application No. 17866284.
Office Action dated Sep. 3, 2020 in European Application No. 17866284.
Office Action dated Mar. 23, 2022 in Chinese Application No. 2017800805197.
Office Action dated Mar. 25, 2021 in Japanese Application No. 2019-543187.
Office Action dated Aug. 5, 2021 in Japanese Application No. 2019-543187.
Office Action dated Jan. 12, 2022 in Japanese Application No. 2019-543187.
Preliminary Office Action dated Jan. 24, 2022 in Brazilian Application No. 112019008325-1.
Office Action dated Feb. 16, 2023 in Japanese Application No. 2021-197842.
Office Action dated Jul. 8, 2019 in U.S. Appl. No. 15/884,845.
Final Office Action dated Oct. 24, 2019 in U.S. Appl. No. 15/884,845.
International Search Report and Written Opinion dated Apr. 26, 2019 in PCT/US19/15946.
Office Action dated Dec. 9, 2021 in Japanese Application No. 2020-540800.
Office Action dated Apr. 27, 2023 in Japanese Application No. 2022-086976.
Office Action dated Nov. 5, 2020 in Australian Application No. 2019214987.
Office Action dated Oct. 15, 2021 in Australian Application No. 2019214987.
Office Action dated Mar. 27, 2023 in Australian Application No. 2022200666.
Office Action dated Oct. 25, 2018 in U.S. Appl. No. 15/791,279.
Final Office Action dated Mar. 1, 2019 in U.S. Appl. No. 15/791,279.
Office Action dated Mar. 1, 2022 in U.S. Appl. No. 16/659,011.
Final Office Action dated Jun. 21, 2022 in U.S. Appl. No. 16/659,011.
Office Action dated Feb. 27, 2023 in U.S. Appl. No. 16/659,011.
Office Action dated Apr. 20, 2023 in JP Application No. 2022-124717.
Notice of Allowance dated Dec. 4, 2023 in U.S. Application No.
Office Action dated Nov. 30, 2023 in Japanese Application No. 2021-197842.
Notice of Allowance dated Jan. 18, 2024 in Japanese Application No. 2022-086976.
Jan. 11, 2024 in JP Application No. 2021-166902.
Office Action dated Dec. 12, 2023 in European Application No. 17866273.0-1122.
Related Publications (1)
Number Date Country
20220117751 A1 Apr 2022 US
Continuations (2)
Number Date Country
Parent 16725790 Dec 2019 US
Child 17566146 US
Parent 15457470 Mar 2017 US
Child 16725790 US